Scotia Capital’s Tenax Therapeutics TENX Stock Holding History

Scotia Capital’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3	Closed	-$218K	–	766
2016 Q1	$218K	Buy	+3	New	+$233K	﹤0.01%	615

Other funds holding TENX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Bank of New York Mellon

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Scotia Capital's TENX Position: Q2 2016 in Review

Scotia Capital sold out of Tenax Therapeutics (TENX) in Q2 2016, closing a stake of 3 shares — an estimated $218K sold.

Scotia Capital first reported a position in TENX in Q1 2016 and held it in 1 quarter. The position peaked at $218K in Q1 2016. 22 funds tracked by Wall St. Rank hold TENX as of Q2 2016.

Scotia Capital reported no remaining Tenax Therapeutics position as of Q2 2016 after selling out during the quarter.
Scotia Capital sold 3 Tenax Therapeutics shares in Q2 2016, an estimated $218K.
Scotia Capital first reported a position in Tenax Therapeutics in Q1 2016 and held it in 1 quarter.
Scotia Capital's Tenax Therapeutics position peaked at $218K in Q1 2016.
22 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2016.

Based on Scotia Capital's 13F filing for Q2 2016, filed 11 Aug 2016.